Enlicitide chloride Drug Asset Due Diligence Report 2026

This Enlicitide chloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Enlicitide chloride can convert its Synthetic peptide, Cyclic Peptide profile and PCSK9 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Enlicitide chloride (query alias: enlicitide decanoate)
Modality / target	Synthetic peptide, Cyclic Peptide; PCSK9; PCSK9 inhibitors
Highest global status	NDA/BLA
Originator	Merck Sharp & Dohme Corp.
Active developers	Merck Sharp & Dohme LLC, MSD R&D (China) Co. Ltd., Merck Sharp & Dohme Corp.

The MCP disease footprint includes Complex dyslipidemia, Primary hypercholesterolemia, Atherosclerosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07614984	Phase 2	Recruiting	750	Percent Change from Baseline in Lipoprotein (a) (Lp(a)) at Week 8
NCT07300280	Phase 1	Recruiting	60	Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Enlicitide
NCT07619443	Phase 1	Recruiting	30	Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

1246-OR: Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, in Participants with and without Diabetes Mellitus in a Pooled Analysis of Two Phase 3 Trials

Phase 3; n=3212; evaluation: Positive. Reported fields: LDL-C(24-week) = -61.0 % ; LDL-C(24-week) = -65.0 %

An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Enlicitide in Participants With Hepatic Impairment

Phase 1; n=20; evaluation: not stated. Reported fields: Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide(Geometric Mean) = 540 nM·hr (Geometric Coefficient of Variation, 36.7); Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide(Geometric Mean) = 559 nM·hr (Geometric Coefficient of Variation, 43.8); Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide(Geometric Mean): GMR = 0.97(90% CI, 0.71 - 1.31)

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia

Phase 3; n=301; evaluation: not stated. Reported fields: Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56(Mean): Difference in Means = -56.7(95% CI, -64.3 to -49.0), P-Value = <0.001; Difference in Means = -36.0(95% CI, -41.8 to -30.2), P-Value = <0.001; Difference in Means = -28.1(95% CI, -33.6 to -22.6), P-Value = <0.001; Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56(Mean) = -64.6 Percent Change (95% Confidence Interval, -68.3 to -60.9); Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56(Mean): Difference in Means = -56.7(95% CI, -64.3 to -49.0), P-Value = <0.001; Difference in Means = -36.0(95% CI, -41.8 to -30.2), P-Value = <0.001; Difference in Means = -28.1(95% CI, -33.6 to -22.6), P-Value = <0.001

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Enlicitide chloride addresses Complex dyslipidemia, Primary hypercholesterolemia, Atherosclerosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 30 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PCSK9 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-02-03	康方生物就创新型PCSK9单抗中国商业化权益与济川药业达成合作，共同推进心血管领域高质量发展	Approved	Financial terms not disclosed
2025-12-11	Everest Medicines entered into a License Agreement with Hasten Biopharmaceutical granting Everest the exclusive license to develop, register and commercialize Lerodalcibep	NDA/BLA	US$29.0M upfront; US$310.0M milestones
2025-08-13	Bluemtec to distribute Novartis Korea's Leqvio to neighborhood clinics	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO